# CORRECTING and REPLACING Scholar Rock Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights
Canonical URL: https://biopharmsignal.com/news/SRRK/correcting-and-replacing-scholar-rock-reports-fourth-quarter-and-full-year-2025-financial-results-and-recent-business-highlights
Ticker: SRRK
Company: Scholar Rock
Source: Scholar Rock
Published: 2026-03-03 12:00 EST
Original Source URL: https://investors.scholarrock.com
## Summary

Apitegromab Biologics License Application (BLA) resubmission and U.S. launch, following FDA approval, are anticipated in 2026 for the treatment of children and adults with spinal muscular atrophy (SMA) FDA completed constructive meeting with Catalent Indiana, LLC (part of Novo Nordisk), with

## Article Body
Apitegromab Biologics License Application (BLA) resubmission and U.S. launch, following FDA approval, are anticipated in 2026 for the treatment of children and adults with spinal muscular atrophy (SMA) FDA completed constructive meeting with Catalent Indiana, LLC (part of Novo Nordisk), with
## Recent Company News
- 2026-07-20 12:00 EST — [Scholar Rock Provides Update on Timing of Committee for Medicinal Products for Human Use (CHMP) Opinion for Apitegromab Marketing Authorisation Application (MAA) for Spinal Muscular Atrophy (SMA)](https://biopharmsignal.com/news/SRRK/scholar-rock-provides-update-on-timing-of-committee-for-medicinal-products-for-h-018ed6e6) — Source: Scholar Rock
- 2026-07-17 20:15 EST — [Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/SRRK/scholar-rock-reports-new-employee-inducement-grants-under-nasdaq-listing-rule-56-f0ff2185) — Source: Scholar Rock
- 2026-07-16 12:00 EST — [Scholar Rock to Report Second Quarter 2026 Financial Results on August 6, 2026](https://biopharmsignal.com/news/SRRK/scholar-rock-to-report-second-quarter-2026-financial-results-on-august-6-2026-4387875b) — Source: Scholar Rock
- 2026-06-22 12:00 EST — [Scholar Rock to Showcase Neuromuscular Research Portfolio at 2026 Annual Cure SMA Research and Clinical Care Meeting and 2026 International Research Congress on FSHD](https://biopharmsignal.com/news/SRRK/scholar-rock-to-showcase-neuromuscular-research-portfolio-at-2026-annual-cure-sm-c0fc71a6) — Source: Scholar Rock
- 2026-06-12 20:15 EST — [Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/SRRK/scholar-rock-reports-new-employee-inducement-grants-under-nasdaq-listing-rule-56-77f7a745) — Source: Scholar Rock
## Related News
- 2026-07-29 13:00 EST — ENLV — [Enlivex Management to Host Webinar to Discuss Capital Strategy, Rain Protocol Treasury Strategy, and Recent Clinical Milestones](https://biopharmsignal.com/news/ENLV/enlivex-management-to-host-webinar-to-discuss-capital-strategy-rain-protocol-tre-5921a627)
- 2026-07-29 12:30 EST — PRGO — [Perrigo to Present at the Canaccord 46th Annual Growth Conference](https://biopharmsignal.com/news/PRGO/perrigo-to-present-at-the-canaccord-46th-annual-growth-conference-40431922)
- 2026-07-29 12:30 EST — LIXT — [NOMAD Announces Operational Deployment of Two Mobile Battery Systems by DSO Electric Cooperative](https://biopharmsignal.com/news/LIXT/nomad-announces-operational-deployment-of-two-mobile-battery-systems-by-dso-elec-7fc12a2c)
- 2026-07-29 12:30 EST — RNXT — [RenovoRx to Host Second Quarter 2026 Financial Results and Business Highlights Conference Call on August 12th at 4:30 p.m. ET](https://biopharmsignal.com/news/RNXT/renovorx-to-host-second-quarter-2026-financial-results-and-business-highlights-c-8bed10ec)
- 2026-07-29 12:25 EST — ICCM — [IceCure: SIO Petitions NCCN to Include Cryoablation in Breast Cancer Treatment Guidelines, Citing IceCure's FDA Clearance  of ProSense®](https://biopharmsignal.com/news/ICCM/icecure-sio-petitions-nccn-to-include-cryoablation-in-breast-cancer-treatment-gu-bec46cd3)